Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Cited by (1,010)

Items 501–600 of 1,010

1. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy
   Eric Huttenlocher Bent, Luis R. Millán-Barea, Iris Zhuang, Daniel R. Goulet, Julia Fröse, Michael T. Hemann · 2021 · Nature Communications
2. Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation
   Jason W.‐L. Eng, Chelsey B. Reed, Kathleen M. Kokolus, Rose Pitoniak, Adam T. Utley, Mark J. Bucsek, Wen Wee Ma, Elizabeth A. Repasky, Bonnie Lee Hylander · 2015 · Nature Communications
3. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype
   Daniel Hirschhorn-Cymerman, Sadna Budhu, Shigehisa Kitano, Cailian Liu, Feng Zhao, Hong Zhong, Alexander M. Lesokhin, Francesca Avogadri-Connors, Jianda D. Yuan, Yanyun Li et al. · 2012 · The Journal of Experimental Medicine
4. Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines
   Jing Liu, Si Si Liew, Jun Wang, Kanyi Pu · 2021 · Advanced Materials
5. Toll-Like Receptor 4 Activation in Cancer Progression and Therapy
   Alja Oblak, Roman Jerala · 2011 · Clinical and Developmental Immunology
6. Size-Dependent Effects of Gold Nanoparticles Uptake on Maturation and Antitumor Functions of Human Dendritic Cells In Vitro
   Sergej Tomić, Jelena Đokić, Saša Vasilijić, Nina Ogrinc, Rebeka Rudolf, Primož Pelicon, Dragana Vučević, Petar Milosavljević, Srđa Janković, Ivan Anžel et al. · 2014 · PLoS ONE
7. Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response
   Chih-Long Chang, Yun-Ting Hsu, Chao-Chih Wu, Yan-Zen Lai, Connie Wang, Yuh‐Cheng Yang, T.‐C. Wu, Chien‐Fu Hung · 2012 · Cancer Research
8. Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors
   Zinal S. Chheda, Rajesh Kumar Sharma, Venkatakrishna Rao Jala, Andrew David Luster, Bodduluri Haribabu · 2016 · The Journal of Immunology
9. Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy
   Madiha Saeed, Jing Xing Gao, Yang Shi, Twan Lammers, Haijun Yu · 2019 · Theranostics
10. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma
    Mei-Chi Hsu, Jenn‐Ren Hsiao, Kung‐Chao Chang, Yuan-Hua Wu, Ih‐Jen Su, Ying‐Tai Jin, Yao Chang · 2010 · Modern Pathology
11. The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?
    Zishuo I. Hu, Heather L. McArthur, Alice Y. Ho · 2017 · Current Breast Cancer Reports
12. Beyond symptomatic relief for chemotherapy‐induced peripheral neuropathy: Targeting the source
    Jiacheng Ma, Annemieke Kavelaars, Patrick M. Dougherty, Cobi J. Heijnen · 2018 · Cancer
13. Cold atmospheric plasma delivery for biomedical applications
    Zhitong Chen, Guojun Chen, Richard A. Obenchain, Rui Zhang, Fan Bai, Tianxu Fang, Hanwen Wang, Yingjie Lu, Richard E. Wirz, Zhen Gu · 2022 · Materials Today
14. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
    Ramon Kaneno, Galina V. Shurin, Irina L. Tourkova, Michael R. Shurin · 2009 · Journal of Translational Medicine
15. Trial Watch
    Erika Vacchelli, Alexander M.M. Eggermont, Catherine Sautès‐Fridman, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2013 · OncoImmunology
16. Innate apoptotic immunity: the calming touch of death
    Raymond B. Birge, David S. Ucker · 2008 · Cell Death and Differentiation
17. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors
    Anja Derer, Benjamin Frey, Rainer Fietkau, Udo S. Gaipl · 2015 · Cancer Immunology Immunotherapy
18. Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors
    Abraham G. Lin, Bo Xiang, Dante J. Merlino, Trevor R. Baybutt, Joya Sahu, Alexander Fridman, Adam Eugene Snook, Vandana Miller · 2018 · OncoImmunology
19. Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling
    Michael Tang, Jun Diao, Hongtao Gu, Ismat A. Khatri, Jun Zhao, Mark S. Cattral · 2015 · Cell Reports
20. CD8+ T Cell Priming by Dendritic Cell Vaccines Requires Antigen Transfer to Endogenous Antigen Presenting Cells
    Alice W. Yewdall, Scott B. Drutman, Felecia Jinwala, Keith S. Bahjat, Nina Bhardwaj · 2010 · PLoS ONE
21. Inflammation and Cancer: A Double-Edged Sword
    Thorsten Hagemann, Frances R. Balkwill, Toby Lawrence · 2007 · Cancer Cell
22. Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1
    Guo‐Yun Chen, Nicholas K. Brown, Wei Wu, Zahra Khedri, Hai Yu, Xi Chen, Diantha van de Vlekkert, Alessandra d’Azzo, Pan Zheng, Yang Liu · 2014 · eLife
23. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
    Maria Vittoria Dieci, Aleix Prat, Enrico Tagliafico, Laia Paré, Guido Ficarra, Giancarlo Bisagni, Federico Piacentini, Daniele Generali, PierFranco Conte, Valentina Guarneri · 2016 · Annals of Oncology
24. NK cell–mediated killing of target cells triggers robust antigen-specific T cell–mediated and humoral responses
    Philippe Krebs, Michael J. Barnes, Kristin Lampe, Karen Whitley, Keith S. Bahjat, Bruce Beutler, Edith M. Janssen, Kasper H. N. Hoebe · 2009 · Blood
25. Programmed Necrosis
    Lorenzo Galluzzi, Tom Vanden Berghe, Nele Vanlangenakker, Sabrina Büttner, Tobias Eisenberg, Peter Vandenabeele, Frank Madeo, Guido Kroemer · 2011 · International review of cytology
26. Fe(III)-Chelated Polydopamine Nanoparticles for Synergistic Tumor Therapies of Enhanced Photothermal Ablation and Antitumor Immune Activation
    Na Xu, Ao Hu, Ximing Pu, Jiangfeng Li, Xingming Wang, Juan Wang, Zhongbing Huang, Xiaoming Liao, Guangfu Yin · 2022 · ACS Applied Materials & Interfaces
27. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
    Sayuri Miyauchi, Sangwoo S. Kim, John Pang, Kathryn Ann Gold, Jorge Silvio Gutkind, Joseph A. Califano, Loren K. Mell, Ezra E.W. Cohen, Andrew B. Sharabi · 2019 · Clinical Cancer Research
28. Rational combinations of immunotherapy with radiotherapy in ovarian cancer
    Fernanda Gabriela Herrera, Melita B. Irving, Lana Elias Kandalaft, George Coukos · 2019 · The Lancet Oncology
29. Trial watch
    Lorenzo Galluzzi, Laura Senovilla, Erika Vacchelli, Alexander M.M. Eggermont, Wolf H. Fridman, Jérôme Galon, Catherine Sautès‐Fridman, Éric Tartour, Laurence Zitvogel, Guido Kroemer · 2012 · OncoImmunology
30. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance
    Madhav V. Dhodapkar, Kavita M. Dhodapkar, Anna Karolina Palucka · 2007 · Cell Death and Differentiation
31. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses
    De Yang, Yuri V. Postnikov, Yana Li, Poonam Tewary, Gonzalo de la Rosa, Feng Wei, Dennis M. Klinman, Theresa L. Gioannini, Jerrold P Weiss, Takashi Furusawa et al. · 2011 · The Journal of Experimental Medicine
32. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns
    Liu, Yang, Chen, Guo-Yun, Zheng, Pan · 2009 · Trends in Immunology
33. NK Cells in the Tumor Microenvironment
    Camille Guillerey · 2020 · Advances in experimental medicine and biology
34. Signaling Through OX40 Enhances Antitumor Immunity
    Shawn M. Jensen, Levi D. Maston, Michael J. Gough, Carl E. Ruby, William L. Redmond, Marka R. Crittenden, Yuhuan Li, Sachin Puri, Christian Heinrich Poehlein, Nick P. Morris et al. · 2010 · Seminars in Oncology
35. Application of Protein Microarrays for Multiplexed Detection of Antibodies to Tumor Antigens in Breast Cancer
    Karen S. Anderson, Niroshan Ramachandran, Jessica Wong, Jacob V. Raphael, Eugenie Hainsworth, Gokhan Demirkan, Daniel William Cramer, Dina Aronzon, Frank Stephen Hodi, Lyndsay N. Harris et al. · 2008 · Journal of Proteome Research
36. The three main stumbling blocks for anticancer T cells
    Lukas Baitsch, Silvia A. Fuertes Marraco, Amandine Legat, Christiane Meyer, Daniel E. Speiser · 2012 · Trends in Immunology
37. Dendritic Cells and Damage-Associated Molecular Patterns: Endogenous Danger Signals Linking Innate and Adaptive Immunity
    Gary Nace, John W. Evankovich, Raymond E. Eid, Allan Tsung · 2011 · Journal of Innate Immunity
38. Combining chemotherapy with PD-1 blockade in NSCLC
    Matthen Mathew, Thomas Enzler, Catherine A. Shu, Naiyer A. Rizvi · 2018 · Pharmacology & Therapeutics
39. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
    Simon J. Dovedi, Monique H. M. Melis, Robert W. Wilkinson, Amy L. Adlard, Ian James Stratford, Jamie Honeychurch, Tim Illidge · 2012 · Blood
40. Immune-enhancing activity of polysaccharides from Hibiscus sabdariffa Linn. via MAPK and NF-kB signaling pathways in RAW264.7 cells
    Chunyan Shen, Wenli Zhang, Jian‐Guo Jiang · 2017 · Journal of Functional Foods
41. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity
    Suah Yang, Man Kyu Shim, Woo Jun Kim, Jiwoong Choi, Gi‐Hoon Nam, Jeongrae Kim, Jinseong Kim, Yujeong Moon, Han Young Kim, Jooho Park et al. · 2021 · Biomaterials
42. A Phase II Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinoma– CA 209-678
    David Wai-Meng Tai, Kelvin Siu Hoong Loke, Apoorva Gogna, Neslihan Arife Kaya, Sze Huey Tan, Tiffany Priyanthi Hennedige, David Chee‐Eng Ng, Farah Gillian Irani, Joycelyn Jie Xin Lee, Jia Qi Lim et al. · 2021 · The Lancet. Gastroenterology & hepatology
43. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
    Zhao, Tiansuo, Ren, He, Jia, Li, Chen, Jing, Xin, Wen, Yan, Fan, Li, Jing, Wang, Xiuchao, Gao, Song, Qian, Dong et al. · 2015 · Oncotarget
44. The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors
    James W. Hodge, Andressa Ardiani, Benedetto Farsaci, Anna R. Kwilas, Sofia R. Gameiro · 2012 · Seminars in Oncology
45. Antitumor immune responses induced by ionizing irradiation and further immune stimulation
    Benjamin Frey, Yvonne Rubner, Lorenz Kulzer, Nina Werthmöller, Eva‐Maria Weiss, Rainer Fietkau, Udo S. Gaipl · 2013 · Cancer Immunology Immunotherapy
46. The oncolytic peptide LTX-315 triggers immunogenic cell death
    Heng Zhou, Sabrina Forveille, Allan Sauvat, Takahiro Yamazaki, Laura Senovilla, Yuting Ma, Peng Liu, Heng Yang, Lucillia Bezu, Kévin Müller et al. · 2016 · Cell Death and Disease
47. Anticancer metal drugs and immunogenic cell death
    Alessio Terenzi, Christine Pirker, Bernhard K. Keppler, Walter Berger · 2016 · Journal of Inorganic Biochemistry
48. Extracellular nucleosides and nucleotides as immunomodulators
    Oliver Kepp, Friedemann Loos, Peng Liu, Guido Kroemer · 2017 · Immunological Reviews
49. Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi, Kazuhiko Nakagawa · 2019 · International Journal of Clinical Oncology
50. Immunogenic ferroptosis and where to find it?
    Robin Demuynck, Iuliia Efimova, Faye Naessens, Dmitri V. Krysko · 2021 · Journal for ImmunoTherapy of Cancer
51. Hyperthermia on immune regulation: A temperature’s story
    Hua-Gang Zhang, Keyur Mehta, Patrice Cohen, Chandan Guha · 2008 · Cancer Letters
52. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen
    Stefanie K. Wculek, J. Amores, Ruth Conde‐Garrosa, Sofía C. Khouili, Ignacio Melero, David Sancho · 2019 · Journal for ImmunoTherapy of Cancer
53. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
    Junyan Li, Yu‐Pei Chen, Ying‐Qin Li, Na Liu, Jun Ma · 2021 · Molecular Cancer
54. DCN released from ferroptotic cells ignites AGER-dependent immune responses
    Jiao Liu, Shan Zhu, Ling Zeng, Jingbo Li, Daniel J. Klionsky, Guido Kroemer, Jianxin Jiang, Daolin Tang, Rui Kang · 2021 · Autophagy
55. High Mobility Group Box‐1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice
    Xiaodong Ge, Elena Arriazu, Fernando Magdaleno, Daniel James Antoine, Rouchelle dela Cruz, Neil David Theise, Natalia Nieto · 2018 · Hepatology
56. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages
    Emeric Limagne, Marion Thibaudin, Lisa Nuttin, Aodrenn Spill, Valentin Dérangère, Jean-David Fumet, Nadia Amellal, Elisa Peranzoni, Valérie Cattan, François Ghiringhelli · 2019 · Cancer Immunology Research
57. A Large Cohort Study Reveals the Association of Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio with Favorable Prognosis in Nasopharyngeal Carcinoma
    Jing Li, Rou Jiang, Wen-Sheng Liu, Qing Liu, Miao Xu, Qi-Sheng Feng, Li-Zhen Chen, Jin‐Xin Bei, Ming‐Yuan Chen, Yi‐Xin Zeng · 2013 · PLoS ONE
58. HMGB1: a two-headed signal regulating tumor progression and immunity
    Lara Campana, Lidia Bosurgi, Patrizia Querini Rovere · 2008 · Current Opinion in Immunology
59. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
    Martin Sebastian, Alexandros Papachristofilou, Christian Weiß, Martin Früh, Richard L. Cathomas, Wolfgang Hilbe, Thomas Wehler, Gerd Rippin, Sven Dominik Koch, Birgit Scheel et al. · 2014 · BMC Cancer
60. Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms
    Hannah R. Wardill, Rachel J. Gibson, Ysabella Z. A. Van Sebille, Kate R. Secombe, Janet K. Coller, Imogen A. White, Jim Manavis, Mark Rowland Hutchinson, Vasiliki Staikopoulos, Richard M. Logan et al. · 2016 · Molecular Cancer Therapeutics
61. In vitro and in vivo immunomodulatory activity of sulfated polysaccharide from Porphyra haitanensis
    Qingmei Liu, Sha-sha Xu, Long Li, Tzu‐Ming Pan, Chao-lan Shi, Hong Liu, Min‐Jie Cao, Wen‐Jin Su, Guangming Liu · 2017 · Carbohydrate Polymers
62. Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
    Ben Wylie, Christophe Macri, Justine D. Mintern, Jason C. Waithman · 2019 · Cancers
63. Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives
    H. Mirghani, Furrat Amen, Yungan Tao, Éric Deutsch, Antonin Lévy · 2015 · Cancer Treatment Reviews
64. The Nuclear Factor κB pathway: A link to the immune system in the radiation response
    Christine Elisabeth Hellweg · 2015 · Cancer Letters
65. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
    Abdul Qader Sukkurwala, Sandy Adjemian, Laura Senovilla, Mickaël Michaud, Sabrina Spaggiari, Erika Vacchelli, Elisa Elena Baracco, Lorenzo Galluzzi, Laurence Zitvogel, Oliver Kepp et al. · 2014 · OncoImmunology
66. Toll-like receptors expressed in tumor cells: targets for therapy
    Li Yu, Shangwu Chen · 2008 · Cancer Immunology Immunotherapy
67. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer
    Joji Kitayama, Koji Yasuda, Kazushige Kawai, Eiji Sunami, Hirokazu Nagawa · 2010 · Radiation Oncology
68. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
    Stephen James Luen, Peter Stephen Savas, Stephen B. Fox, Roberto Salgado, Sherene Loi · 2017 · Pathology
69. Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy
    Flavia Radogna, Marc F. Diederich · 2018 · Biochemical Pharmacology
70. Radiation therapy-induced remodeling of the tumor immune microenvironment
    Maud Charpentier, Sheila Spada, Samantha J. Van Nest, Sandra Demaria · 2022 · Seminars in Cancer Biology
71. Vascular CD39/ENTPD1 Directly Promotes Tumor Cell Growth by Scavenging Extracellular Adenosine Triphosphate
    Lili Feng, Xiaofeng Sun, Eva Csizmadia, Lihui Han, Bian Shu, Takashi Murakami, Xin Wang, Simon Christopher Robson, Yan Wu · 2011 · Neoplasia
72. CD8+ and FOXP3+ Tumor-Infiltrating T Cells Before and After Chemoradiotherapy for Rectal Cancer
    Eiji Shinto, Kazuo Hase, Yojiro Hashiguchi, Akinori Sekizawa, Hideki Ueno, Atsushi Shikina, Yoshiki Kajiwara, Hirotoshi Kobayashi, Megumi Ishiguro, Junji Yamamoto · 2014 · Annals of Surgical Oncology
73. Immune-mediated mechanisms influencing the efficacy of anticancer therapies
    Seth B. Coffelt, Karin E. de Visser · 2015 · Trends in Immunology
74. Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death
    Roberta Zappasodi, Serenella Maria Pupa, Gaia Cristina Ghedini, Italia Bongarzone, Michele Magni, Antonello Domenico Cabras, Mario P. Colombo, Carmelo Carlo‐Stella, Alessandro M. Gianni, Massimo Di Nicola · 2010 · Cancer Research
75. Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity
    Valerie R. Wiersma, Marek Michalak, Trefa Mohammed Abdullah, Edwin Bremer, Paul Eggleton · 2015 · Frontiers in Oncology
76. Experimental mouse tumour models: what can be learnt about human cancer immunology?
    Glenn Dranoff · 2011 · Nature reviews. Immunology
77. The roles of FADD in extrinsic apoptosis and necroptosis
    Eun‐Woo Lee, Jin-Ho Seo, Man-Hyung Jeong, Sang-sik Lee, Jae-Whan Song · 2012 · BMB Reports
78. Tumor microenvironment-mediated chemoresistance in breast cancer
    Kobra Velaei, Nasser Samadi, Balal Brazvan, Jafar Soleimani Rad · 2016 · The Breast
79. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy
    Mingxia Jiang, Jun Zeng, Liping Zhao, Mogen Zhang, Jinlong Ma, Xiuwen Guan, Weifen Zhang · 2021 · Nanoscale
80. Nanomedicine for brain cancer
    Sabina Quader, Kazunori Kataoka, Horacio Cabral · 2022 · Advanced Drug Delivery Reviews
81. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
    Yun Hua Lee, David Wai-Meng Tai, Connie Yip, Su Pin Choo, Valerie Chew · 2020 · Frontiers in Immunology
82. Dendritic Cells in Cancer Immunology and Immunotherapy
    Laura Hato, Ángel Vizcay Atienza, Iñaki Eguren‐Santamaría, José Luis Perez‐Gracia, Javier Rodríguez, Jaime Gállego Pérez‐Larraya, Pablo Sarobe, Susana Inogés, Ascensión López Díaz de Cerio, Marta Santisteban · 2024 · Cancers
83. Pentraxins, humoral innate immunity and tissue injury
    Angelo Andrea Manfredi, Patrizia Querini Rovere, Barbara Bottazzi, Cecília Garlanda, Alberto Mantovani · 2008 · Current Opinion in Immunology
84. Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
    Elham Beyranvand Nejad, Tetje Cornelia van der Sluis, Suzanne van Duikeren, Hideo Yagita∥, George M. C. Janssen, Peter A. van Veelen, Cornelis J.M. Melief, Sjoerd H. van der Burg, Ramon Arens · 2016 · Cancer Research
85. STING, DCs and the link between innate and adaptive tumor immunity
    Ralph E. Vatner, Edith M. Janssen · 2017 · Molecular Immunology
86. PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death
    Max Jing Rui Tham, Maria V. Babak, Wee Han Ang · 2020 · Angewandte Chemie International Edition
87. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer
    Koji Yasuda, Takako Nirei, Eiji Sunami, Hirokazu Nagawa, Joji Kitayama · 2011 · Radiation Oncology
88. Next-Generation Cancer Immunotherapy Targeting Glypican-3
    Yasuhiro Shimizu, Toshihiro Suzuki, Toshiaki Yoshikawa, Itaru Endo, Tetsuya Nakatsura · 2019 · Frontiers in Oncology
89. Polysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapy
    Qihang Shang, Xiaoyun Yu, Qi Sun, Huayao Li, Changgang Sun, Lijuan Liu · 2023 · Biomedicine & Pharmacotherapy
90. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
    Emanuela Dell’Aquila, Chiara Cremolini, Tea Zeppola, Sara Lonardi, Francesca Bergamo, Gianluca Masi, Marco Stellato, Federica Marmorino, Marta Schirripa, Federica Urbano et al. · 2018 · Annals of Oncology
91. Regulation by Reversible S-Glutathionylation: Molecular Targets Implicated in Inflammatory Diseases
    Melissa D. Shelton, John J. Mieyal · 2008 · Molecules and Cells
92. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation
    Jeremy G. Price, Juliana Idoyaga, Hélène Salmon, Brandon Hogstad, Carolina L. Bigarella, Saghi Ghaffari, Marylène Leboeuf, Miriam Mérad · 2015 · Nature Immunology
93. Cross-priming in cancer immunology and immunotherapy
    Carlos Luri‐Rey, Álvaro Teijeira, Stefanie K. Wculek, Carlos E. de Andrea, Claudia Herrero, Álvaro López‐Janeiro, Maria Esperanza Rodriguez-Ruiz, Ignacio Heras‐Murillo, Maria Aggelakopoulou, Pedro Berraondo et al. · 2025 · Nature reviews. Cancer
94. Toll-like receptors, wound healing, and carcinogenesis
    Johannes Kluwe, Ali M. Mencin, Robert F. Schwabe · 2008 · Journal of Molecular Medicine
95. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies
    Simon Gebremeskel, Brent Johnston · 2015 · Oncotarget
96. Regulation of Posttranslational Modifications of HMGB1 During Immune Responses
    Yiting Tang, Xin Sheng Zhao, Daniel James Antoine, Xianzhong Xiao, Haichao Wang, Ulf Andersson, Timothy R. Billiar, Kevin J. Tracey, Ben Lü · 2015 · Antioxidants and Redox Signaling
97. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications
    Jessica P Roelands, Peter J.K. Kuppen, Louis Vermeulen, Cristina Maccalli, Julie V. Decock, Ena Wang, Francesco Maria Marincola, Davide Bedognetti, Wouter Hendrickx · 2017 · International Journal of Molecular Sciences
98. Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells
    Julia Krombach, Roman Hennel, Nikko Brix, Michael Orth, Ulrike Schötz, Anne Ernst, Jessica Schuster, Gabriele Zuchtriegel, Christoph Andreas Reichel, Susanne Bierschenk et al. · 2018 · OncoImmunology
99. A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy
    Hathaichanok Phuengkham, Chanyoung Song, Yong Taik Lim · 2019 · Advanced Materials
100. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells
     José Ignácio Gonzalez Solari, Eduardo Cremonese Filippi‐Chiela, Emily Ferreira Salles Pilar, Vitória Brum da Silva Nunes, Esteban Alberto Gonzalez, Fabrício Figueiró, C Andrade, Fábio Klamt · 2020 · BMC Cancer